文献速递神经肿瘤功能神经外科

拉考沙胺单药治疗脑肿瘤相关癫痫:意大利多中心回顾性研究结果

Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study.
PubMed 文献 · J Neurooncol · 2022-04-09

该研究纳入意大利12个中心的132例原发脑肿瘤患者,评估拉考沙胺单药治疗脑肿瘤相关癫痫的疗效与耐受性。结果显示3个月和6个月无发作率分别为64.4%和55%,不良反应主要为轻度,退出率低(1.5%)。作者认为这是首个显示拉考沙胺单药治疗脑肿瘤相关癫痫有效且耐受性良好的研究,需进一步前瞻性研究确认。

要点

  • 拉考沙胺单药治疗脑肿瘤相关癫痫3个月无发作率为64.4%,6个月为55%。
  • 既往使用两种或以上抗癫痫发作药物者,癫痫控制劣于以拉考沙胺为首选单药者。
  • 不良反应主要为轻度(CTCAE 1-2级),退出率低(1.5%)。

核心结论

  • 这是首个显示拉考沙胺单药治疗脑肿瘤相关癫痫有效且耐受性良好的研究,需进一步前瞻性研究确认这些初步数据,并研究生活质量和神经认知功能。

研究设计与样本

  • 意大利12个中心的多中心回顾性研究,纳入132例接受拉考沙胺单药治疗的原发脑肿瘤患者。
  • 主要终点为3个月和6个月无发作率,次要终点为不良反应和退出率。

主要发现

  • 总体而言,拉考沙胺治疗3个月无发作率为64.4%,6个月为55%。
  • 在拉考沙胺之前使用两种或以上抗癫痫发作药物的患者,癫痫控制劣于以拉考沙胺为首选单药治疗的患者。
  • 14例患者在磁共振(MRI)显示肿瘤进展的情况下仍保持癫痫控制。
  • 多变量分析显示,诊断时全切除与6个月更高的无发作率显著相关。
  • 不良反应主要为轻度(根据CTCAE分类为1-2级),退出率低(1.5%),主要不良反应为头晕和嗜睡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lacosamide (LCM) is a third-generation anti-seizure medication (ASM) approved for focal onset epilepsy in patients aged ≥ 4.378 Previous studies have reported an efficacy of LCM as add-on treatment in brain tumor-related epilepsy (BTRE). To date, there are no studies in the literature focusing on lacosamide used in monotherapy to treat BTRE. In our retrospective study we investigated efficacy and tolerability of LCM in monotherapy in a multicenter national cohort of primary brain tumor patients. METHODS: We collected from 12 Italian Centers 132 patients with primary brain tumors who were treated with LCM in monotherapy. For each patient we evaluated seizure freedom at 3 and 6 months (primary endpoints), side effects and drop-out rate (secondary endpoints). RESULTS: Overall, LCM led to seizure freedom in 64.4% of patients at 3 months and 55% at 6 months. Patients who used two or more ASMs before LCM had a worse seizure control than patients in monotherapy with LCM as first choice. In 14 patients, we observed seizure control despite tumor progression on magnetic resonance (MRI). Multivariate analysis showed that gross-total resection at diagnosis was significantly associated with higher seizure freedom rate at 6 months. Side effects were mainly mild (grade 1-2 according to CTCAE classification) and drop-out rate was low (1.5%). Main side effects were dizziness and somnolence. CONCLUSIONS: This is the first study showing a good efficacy and tolerability of LCM when used in monotherapy in BTRE. Further prospective studies are needed to confirm these preliminary data, investigating also quality of life and neurocognitive functions.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Mo F, Meletti S, Belcastro V, et al. Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study. J Neurooncol. 2022. PMID: 35397759. doi:10.1007/s11060-022-03998-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。